A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jinhee | - |
dc.contributor.author | Kim, Hye-Youn | - |
dc.contributor.author | Hong, Suntaek | - |
dc.contributor.author | Shin, Sarah | - |
dc.contributor.author | Kim, Young Ah | - |
dc.contributor.author | Kim, No Soo | - |
dc.contributor.author | Bang, Ok-Sun | - |
dc.date.available | 2020-02-27T02:23:23Z | - |
dc.date.created | 2020-02-04 | - |
dc.date.issued | 2019-08 | - |
dc.identifier.issn | 0753-3322 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/1121 | - |
dc.description.abstract | BP10A is a novel two-herb medicine formula, consisting of Descurainiae sophia Semen and Peucedani praer-uptorum Radix. This study was done to evaluate the antitumor efficacy of BP10A and its effect on the efficacy of the anticancer drugs oxaliplatin and irinotecan (CPT-11) in a colon tumor xenograft model. Chemical constituents from the ethanol extracts of BP10A were characterized with the ultra-performance liquid chromatography (UPLC) and each constituent was quantified with the UPLC-diode array detector method. Our study showed that BP10A exerted the cytotoxic effects in two colorectal cancer cell lines and its combination treatments with oxaliplatin or CPT-11 remarkably increased the in vitro cytotoxicity of each cancer drug assessed by the Ez-cytox assay. The in vivo antitumor activity of BP10A was evaluated in three colon cancer patient-derived tumor xenograft (PDTX) models with different genetic backgrounds. Oral administration with BP10A (250 and 500 mg/kg, daily) delayed tumor growth by 34-70% in the all PDTX models. Similarly, intraperitoneal injection of oxaliplatin (6 mg/kg) or CPT-11 (20 mg/kg) also suppressed tumor growth by 31.8-60.5% or by 24.3-50.4%, respectively. Furthermore, the combination treatment of BP10A with oxaliplatin or CPT-11 remarkably enhanced the antitumor activity of each anti-cancer drug and delayed tumor growth by 47.1-74.6% or by 74.4-82.9%, respectively. In accordance with the antitumor activity, the Ki-67 expression for tumor cell proliferation and the CD31 for angiogenesis were decreased, and TUNEL staining for tumor cell apoptosis was remarkably increased by the co-treatment of BP10A and the anticancer drugs as well as by each treatment of BP10A, oxaliplatin or CPT-11. Conclusively, BP10A has a strong tumor inhibitory effect against colon cancer and a synergistic effect with anticancer drugs, suggesting that BP10A could be considered as a good therapeutic candidate for the treatment of colon cancer. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER | - |
dc.relation.isPartOf | BIOMEDICINE & PHARMACOTHERAPY | - |
dc.subject | PEUCEDANUM-PRAERUPTORUM DUNN | - |
dc.subject | TUMOR XENOGRAFTS | - |
dc.subject | IN-VITRO | - |
dc.subject | COLORECTAL-CANCER | - |
dc.subject | ISOQUERCITRIN | - |
dc.subject | CONSTITUENTS | - |
dc.subject | GROWTH | - |
dc.subject | DRUG | - |
dc.subject | PYRANOCOUMARINS | - |
dc.subject | COMBINATION | - |
dc.title | A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000471592900007 | - |
dc.identifier.doi | 10.1016/j.biopha.2019.108987 | - |
dc.identifier.bibliographicCitation | BIOMEDICINE & PHARMACOTHERAPY, v.116 | - |
dc.identifier.scopusid | 2-s2.0-85065712208 | - |
dc.citation.title | BIOMEDICINE & PHARMACOTHERAPY | - |
dc.citation.volume | 116 | - |
dc.contributor.affiliatedAuthor | Kim, Hye-Youn | - |
dc.contributor.affiliatedAuthor | Hong, Suntaek | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | BP10A | - |
dc.subject.keywordAuthor | Colon cancer | - |
dc.subject.keywordAuthor | Combination treatment | - |
dc.subject.keywordAuthor | Patient-derived tumor xenograft | - |
dc.subject.keywordAuthor | Synergistic effect | - |
dc.subject.keywordPlus | PEUCEDANUM-PRAERUPTORUM DUNN | - |
dc.subject.keywordPlus | TUMOR XENOGRAFTS | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | ISOQUERCITRIN | - |
dc.subject.keywordPlus | CONSTITUENTS | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordPlus | DRUG | - |
dc.subject.keywordPlus | PYRANOCOUMARINS | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.